Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Prevalence of and risk factors for lipodystrophy among HIVinfected patients receiving combined antiretroviral treatment in the Asia-pacific region: Results from the TREAT asia HIV observational database (TAHOD)
Authors: Sang Hoon Han
Jialun Zhou
Suneeta Saghayam
Sasheela Vanar
Nittaya Phanuphak
Yi Ming A. Chen
Thira Sirisanthana
Somnuek Sungkanuparph
Christopher K.C. Lee
Sanjay Pujari
Patrick C.K. Li
Shinichi Oka
Vonthanak Saphonn
Fujie Zhang
Tuti Parwati Merati
Matthew G. Law
Jun Yong Choi
Yonsei University College of Medicine
Kirby Institute
YR Gaitonde Centre for AIDS Research and Education
University of Malaya
Thai Red Cross AIDS Research Centre
National Yang-Ming University Taiwan
Research Institute for Health Sciences
Mahidol University
Hospital Sungai Buloh
Institute of Infectious Diseases
Queen Elizabeth Hospital Hong Kong
National Center for Global Health and Medicine
National Center for HIV/AIDS
Beijing Ditan Hospital
Universitas Udayana
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine
Issue Date: 11-Jul-2011
Citation: Endocrine Journal. Vol.58, No.6 (2011), 475-484
Abstract: The prevalence of and risk factors for lipodystrophy (LD) among patients receiving combined antiretroviral treatment (cART) in the Asia-Pacific region are largely unknown. LD diagnosis was based on the adverse event definition from the US NIH Division of AIDS (2004 version), and only cases with a severity grade of ≥ 3 were included. TAHOD patients who had recently commenced cART with ≥ 3 drugs after 1996 from sites which had ever reported LD were included in the analysis. Covariates for the forward multivariate logistic regression model included demographic variables, CDC disease classification, baseline CD4 and viral load, hepatitis B/C virus co-infection, and regimen and duration of cART. LD was diagnosed in 217 (10.5%) of 2072 patients. The median duration of cART was 3.8 (interquartile range, 2.2-5.3) years (stavudine, 2.0 (1.0-3.5) years; zidovudine, 1.8 (0.6-3.9) years; and protease inhibitors (PI), 2.6 (1.3-4.5) years). In the multivariate model, factors independently associated with LD included use of stavudine (≤ 2 years vs. no experience: OR 25.46, p < 0.001, > 2 years vs. no experience: OR 14.92, p < 0.001), use of PI ( > 2.6 years vs. no experience: OR 0.26, p < 0.001), and total duration of cART ( > vs. ≤ 3.8 years: OR 4.84, p < 0.001). The use of stavudine was strongly associated with LD in our cohort. Stavudine-sparing cART strategies are warranted to prevent the occurrence of LD in the Asia-Pacific region. ©The Japan Endocrine Society.
ISSN: 13484540
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.